Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the vaccine safeguards at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.

• Nearly 85 per cent protection when vaccinated four weeks before birth
• Maternal antibodies transferred through placenta safeguard newborns from birth
• Coverage achievable with two-week gap before premature birth
• Vaccination in the third trimester still provides meaningful protection for infants

Compelling evidence from current research

The effectiveness of the RSV vaccine administered during pregnancy has been established through a comprehensive study undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s findings have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research gives healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.

The results paint a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers had not received the vaccination. This stark contrast highlights the vaccine’s critical role in preventing serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Study methodology and scope

The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology measured actual clinical results rather than experimental conditions, providing real-world data of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and its dangers

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection triggers deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to feed and breathe properly. Parents often witness their babies visibly struggling, their chests heaving as they try to pull enough air into their weakened respiratory system. Whilst most infants recover with clinical support, a small but significant group succumb from RSV complications each year, making prevention through vaccination a essential public health imperative for defending the most vulnerable and youngest individuals in the population.

• RSV produces inflammation in lungs, causing severe breathing difficulties in infants
• Approximately half of newborns acquire the virus during their first few months alive
• Symptoms vary between minor cold-like symptoms to life-threatening chest infections needing hospital treatment
• More than 20,000 UK babies require serious hospital care for RSV each year
• Small numbers of babies die from RSV related complications each year in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme began in 2024, health officials have emphasised the value of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.

The guidance from public health bodies stays clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the practical demands of pregnancy whilst ensuring strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection irrespective of geographical location.

• NHS trusts rolling out varied communication campaigns to reach expectant mothers
• Regional disparities in immunisation take-up in different parts of England demand focused enhancement
• Community health services tailoring initiatives to align with community needs and circumstances

Practical implications and parental perspectives

The vaccine’s outstanding effectiveness provides concrete gains for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the launch of this protective measure, the 80% reduction in admissions equates to thousands of infants protected against serious illness. Parents no longer face the distressing scenario of watching their newborns struggle for breath or labour to feed, symptoms that define critical RSV illness. The vaccine has markedly changed the picture of neonatal breathing health, giving expectant mothers a preventative option to safeguard their youngest infants during those vital initial period.

For families like that of Malachi, whose severe RSV infection caused severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s support of the jab highlights the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to women in pregnancy navigating their late pregnancy, changing what was once an predictable seasonal threat into a manageable risk.